Migraine

In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson’s treatment and more.

LAS VEGAS — Certain red flags can indicate that a patient’s headaches are the migraine type, Merle Diamond, MD, said at PAINWeek 2022.

In this edition, preventive therapies should be offered for migraines; targeting neuropathic symptoms for poststroke pain; PDE5 inhibitors not associated with lower AD, dementia risk and more.

Premenopausal and perimenopausal women with a history of migraines were more likely to experience poor sleep vs. those who did not have a history of migraines, according to a cross-sectional study presented at the NAMS Annual Meeting.

Fortunately, in recent years, migraine has gained wider public and provider recognition as a complex and serious, chronic neurological disease that can profoundly impact a person’s quality of life.

The 2022 PAINWeek and BRAINWeek conferences, Sept. 6-9 and Sept. 28-30 in Las Vegas, will feature migraine tracks presented by the world-renowned Diamond Headache Clinic.

CHARLOTTE, N.C. — Study participants with a history of migraine experienced less sleep apnea and hypoxia than those without migraine, according to a poster presented at the SLEEP meeting.

For adults with migraine and repeated preventive treatment failures, eptinezumab produced significant reductive effects compared with placebo, along with acceptable safety and tolerability, per a study published in Lancet Neurology.

AbbVie announced it has submitted a supplemental new drug application to the FDA for Qulipta, a preventive migraine treatment for adults.

DENVER — There may be a link between migraine and clinical endocannabinoid deficiency, a speaker said at the American Headache Society’s annual scientific meeting.